| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2026-012 | 湖南九典制药股份有限公司 关于 2026 年第一季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 3、截至2026年第一季度末，九典转02剩余2,052,762张，对应票面金额为 205,276,200元。 根据《深圳证券交易所创业板股票上市规则》有关规定，湖南九典制药股份 有限公司（以下简称"公司"）现将2026年第一季度可转换公司债券（以下简称 "可转债"）转股及公司股份变动情况公告如下： 一、可转换公司债券基本情况 经中国证券监督管理委员会证监许可〔2023〕526 号文同意注册，公司于 2023 年 9 月 15 日向不特定对象发行了 360.00 万张可转债，每张面值 100 元，发行总 额为 36,000.00 万元。 经深圳证券交易所（以下简称"深交所"）同意，公司可转债于 2023 年 10 月 13 日起在深交所挂牌交易，债 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2026-011 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的《药品注册证书》。现将相关情况公告如下： 一、证书的主要内容 湖南九典制药股份有限公司 1、药品名称：富马酸依美斯汀缓释胶囊 2、剂型：胶囊剂 3、规格：2mg 4、注册分类：化学药品 3 类 5、申请事项：药品注册（境内生产） 6、证书编号：2026S00772 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的相关情况 富马酸依美斯汀缓释胶囊适用于治疗过敏性鼻炎和荨麻疹，最早于 1993 年 在日本批准上市，目前有缓释胶囊、滴眼液和贴剂在国内外上市销售。 米内数据显示，富马酸依美斯汀缓释胶囊 2022 年、2023 年和 2024 ...

Group 1: Brand Development - The company is expanding its brand presence by targeting retail pharmacies and online platforms while reinforcing its hospital market [2] - A brand upgrade event was held on December 6, 2025, introducing the "Mr. Pain Relief" branding to enhance market competitiveness [2] - The new slogan "For pain relief, choose Jiudian" aims to address consumer pain points and improve brand recognition [2] Group 2: Financial Performance and Market Strategy - The implementation of centralized procurement for the Loxoprofen Sodium Gel Patch may lead to a temporary decline in gross margin due to price adjustments [3] - In 2026, the company plans to stabilize existing business while driving innovation, focusing on both hospital and retail markets [3] - The company has 18 products eligible for continued procurement under national centralized purchasing agreements, which will support sales and market expansion [3] Group 3: Product Development and Innovation - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of 2026 and initiate Phase II trials [4] - The company has established a clear and competitive matrix of external products, including Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, with significant advantages in exclusivity and insurance coverage [4] - The company aims to enhance its product offerings to meet diverse clinical and consumer needs, particularly in the traditional plaster market [4] Group 4: Employee Incentives and Corporate Governance - The completed share repurchase plan will primarily be used for employee stock incentives to align interests between the company, shareholders, and core team [4] - Future stock incentive plans will be developed based on market conditions and strategic planning to motivate employees and foster talent [4]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2026-010 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于股东减持股份的预披露公告 股东杨洋保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份 612,087 股（占本公司总股本比例 0.124%）的董事、总经 理杨洋先生，计划在本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方 式减持本公司股份不超过 153,021 股（占本公司总股本比例 0.031%）。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到杨洋先生出具 的《股份减持计划告知函》。现将相关情况公告如下： 一、股东的基本情况 | 股东名称 | 职务 持股总数（股） | 占公司总股本的比例（%） | | | --- | --- | --- | --- | | 杨洋 | 董事、总经理 612,087 | | 0.124 | 注：本公告中计算相关股份 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2026-008 | 湖南九典制药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的《药品注册证书》。现将相关情况公告如下： 一、证书的主要内容 米内数据显示，阿仑膦酸钠 2022 年、2023 年和 2024 年，中国三大终端六 大市场的销售额分别为 61,643 万元、68,534 万元和 72,009 万元。 1、药品名称：阿仑膦酸钠口服溶液 二、药品的相关情况 阿仑膦酸钠口服溶液适用于治疗绝经后妇女的骨质疏松症，以预防髋部和脊 柱骨折（椎骨压缩性骨折），治疗男性骨质疏松症以增加骨量。阿仑膦酸钠最早 于 1995 年在美国批准上市。目前有片剂、肠溶片和口服溶液剂在国内外上市销 售。 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关 ...

湖南九典制药股份有限公司 关于参与国家组织集采药品协议期满品种接续采购 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2026-009 | | --- | --- | --- | | 债券代码：123110 | 债券简称：九典转债 | | 二、本次中选对公司的影响 公司及九典诺纳中选的 18 个药品，2024 年度合计销售收入为 43,140.46 万 元，占公司 2024 年度营业收入比例为 14.72%（数据已经审计）；2025 年前三季 度合计销售收入为 33,483.63 万元，占公司 2025 年前三季度营业收入比例为 14.76%（数据未经审计）。 本次接续采购品种为国家组织集采 1-8 批协议期满的品种，中选结果于 2026 年 3 月份实施，具体执行日期以各地发布通知为准，至 2028 年 12 月 31 日结束。 采购周期中，医疗机构将优先使用本次接续采购中选药品，并确保完成约定采购 量。若后续签订采购协议并实施，将有利于促进上述中选药品的销售和市场拓展， 提升公司的品牌影响力，对公司的长远发展具有积极的影响。 三、风险提示 中选结果的公告 本公司及董事会全体成员保证信息 ...

Group 1: Share Buybacks - Companies such as Zhongshun Jierou and Yuanli Co. have announced new share buyback plans, with Zhongshun Jierou planning to repurchase shares at a price not exceeding 12.4 yuan per share, with a total fund of no less than 60 million yuan and no more than 120 million yuan [1] - Kaipu Cloud plans to repurchase shares with a total fund of no less than 50 million yuan and no more than 100 million yuan, at a price not exceeding 315 yuan per share [1] - Aidi Precision has repurchased 209,000 shares for a total payment of approximately 5.09 million yuan, as part of a buyback plan with a total fund range of 100 million to 200 million yuan [3] Group 2: Shareholder Increases - Conch Cement's controlling shareholder, Conch Group, plans to increase its stake in the company with a minimum investment of 700 million yuan and a maximum of 1.4 billion yuan within six months [2] - Huaneng Hydropower's controlling shareholder's investment fund has increased its stake by 3.276 million shares for a total of 30.02 million yuan, with plans to continue increasing its stake by an estimated total of 100 million to 150 million yuan [2] - Fuguang Co. reported that its controlling shareholder has cumulatively increased its stake by 233,300 shares, costing approximately 6.76 million yuan, with plans for further increases [2] Group 3: Buyback Progress - Xingsui Technology has cumulatively repurchased 2.98 million shares, with total payments exceeding 68.41 million yuan, surpassing the lower limit of its buyback plan [3] - Jiutian Pharmaceutical has completed its buyback plan, having repurchased 6.1808 million shares, accounting for 1.24% of the total share capital, with a total transaction amount reaching 100 million yuan [3]

Core Viewpoint - The company, Jiutian Pharmaceutical, has completed its share repurchase program, acquiring a total of 6.1808 million shares, which represents 1.24% of its total share capital [1] Summary by Categories Share Repurchase Details - The company repurchased shares through a centralized bidding trading method [1] - The highest transaction price was 18.44 yuan per share, while the lowest was 14.51 yuan per share [1] - The total amount spent on the repurchase was 100 million yuan, excluding transaction fees [1]

Group 1 - The company, Jiutian Pharmaceutical, announced the completion of its share repurchase program, having repurchased a total of 6.1808 million shares, which represents 1.24% of its total share capital [1] - The highest transaction price during the repurchase was 18.44 yuan per share, while the lowest was 14.51 yuan per share [1] - The total amount spent on the share repurchase was 100 million yuan, excluding transaction fees [1]